Isolere Bio receives a Phase I SBIR award from NIH to support application of the IsoTag technology to Lentivirus manufacturing

Written By Mike Binder

January 24, 2022, Durham, NC Isolere has received its official Notice of Award from NIGMS to fund its SBIR proposal applying the novel IsoTag technology to lentiviral vectors, which are critical, but expensive tools used in CAR-T and other cell therapies. We are thankful for this funding and its role in supporting the technical feasibility demonstrations for more efficient concentration and purification of higher quality lentivirus.

Mike Binder
Previous

Isolere Bio Enters into Research Collaboration Agreement with Oxford Biomedica to Develop Enabling Manufacturing Technology for Lentiviral Vectors